What Is a Gleason Score for Prostate Cancer?
Learn how a Gleason score is calculated to help determine the aggressiveness of prostate cancer, and how it could influence a patient's treatment.
Progress Against Cancer
Learn how a Gleason score is calculated to help determine the aggressiveness of prostate cancer, and how it could influence a patient's treatment.
Research unveiled at the AACR Annual Meeting 2025 highlighted advances in blood-based liquid biopsy tests to help improve cancer care.
Study examines benefit of PARP inhibitors before surgery in BRCA-related breast cancer, and exercise improves sexual function after prostate cancer treatment.
Clinical trial results reported at the AACR Annual Meeting 2025 showcased new therapeutic approaches for non-small cell lung cancer.
The largest increases were found in breast, colorectal, endometrial, pancreatic, and kidney cancers. Early-onset cancers, or cancers diagnosed in individuals under the age of 50, are rising in the United States. While the exact...
The FDA has approved retifanlimab-dlwr, both alone and in combination with chemotherapy, for certain patients with anal squamous cell carcinoma. The U.S. Food and Drug Administration (FDA) has approved retifanlimab-dlwr (Zynyz) for patients with...
The FDA has approved telisotuzumab vedotin-tllv for certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) for the treatment of adult...
The FDA has approved belzutifan for certain patients with pheochromocytoma and paraganglioma. The U.S. Food and Drug Administration (FDA) has approved belzutifan (Welireg) for the treatment of patients 12 years and older with locally...
During the Presidential Select Symposium at the AACR Annual Meeting 2025, Patricia M. LoRusso, DO, PhD(h), FAACR, led a panel addressing the global cancer burden.
A single dose of HPV vaccine is highly effective, and not all cancers are increasing in people under 50.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More